Posts Tagged ‘AIDS’

9
Sep

HIV

   Posted by: author1    in Diseases

Because there is no vaccine for HIV, the only way people can prevent infection with the virus is to avoid behaviors putting them at risk of infection, such as sharing needles and having unprotected sex.

Many people infected with HIV (AIDS) have no symptoms. Therefore, there is no way of knowing with certainty whether a sexual partner is infected unless he or she has repeatedly tested negative for the virus and has not engaged in any risky behavior.

Abstaining from having sex or using male latex condoms or female polyurethane condoms may offer partial protection, during oral, anal, or vaginal sex. Only water based lubricants can be used when using a condom.

Even though there is some evidence to show spermicides can destroy HIV, it is not proven as a prevention system.

Recently, NIAID-supported two studies that found adult male medical circumcision reduces a man’s risk of acquiring HIV infection by approximately 50 percent. The studies only pertain to heterosexual forms of transmission. As with other prevention strategies, male circumcision is not completely effective at preventing the transmission of HIV. Circumcision will be more effective if it is a part of a more complete prevention strategy that includes condoms.

Vaccines help the body’s immune system to recognize a harmful organism and kill it when the body sees the real thing. Despite extraordinary advances in understanding both HIV and the human immune system, a fully successful HIV vaccine continues to elude researchers. This is why we primarily reley on HIV medications like Kaletra (Lopinavir, Ritonavir), and Combivir.

HIV attacks CD4+ T cells, the most important part of the immune system that coordinates and directs the activities of other types of immune cells that combat intruding microbes. In order for a vaccine to be effective it would need to be able to activate these cells- a hard feat if they are being infected and destroyed by the HIV virus.Scientists have not identified the correlates of immunity, or protection, for HIV and are still trying to design vaccines to induce the appropriate immune responses necessary for protection.

Unlike other viral diseases for which investigators have made successful vaccines, there are no documented cases of complete recovery from HIV infection. So, HIV vaccine research has no actual human model of recovery from an infection and subsequent protection from re-infection to help it. HIV will continually mutate in an infected person while it recombinds to evolve into brand new strains. This extensive diversity of HIV poses a challenge to vaccine design as an HIV vaccine would need to protect against many different strains of the virus circulating throughout the world. Vaccines in the past have only had to fight off a small number of strains, even one.

Tags: , , ,

20
May

Entering HIV Treatment

   Posted by: author1    in Diseases

Each HIV infected patient who is entering into care should have a full medical history, physical, lab evaluation and counseling. This is to confirm the presenence of HIV, get historical and laboratory data, discuss treatment of HIV with patient, and initiate care as suggested by HIV primary care guidelines. Baseline information then is used to define management goals and plans.

A new patient should have the following tests performed on them in their first visits

•  HIV antibody testing (if prior documentation not available) or if HIV RNA is undetectable (AI);
– CD4 + cell count
– HIV RNA (Viral Load);
•  Complete blood count, chemistry profile, transaminase levels, BUN and creatinine, urinalysis, screening test
for syphilis (e.g., RPR, VDRL, or treponema EIA), tuberculin skin test (TST) or interferon-γ release assay
IGRA (unless there is history of a prior TB or positive TST or IGRA), anti Toxoplasma gondii IgG,
hepatitis A, B, and C serologies, and Pap smear in women;
– Fasting blood glucose and serum lipids if the person is considered to be at risk for heart disease and for
baseline evaluation before the start of ARV therapy and
• For patients who have pretreatment HIV RNA >1,000 copies/mL, genotypic resistance testing when the
regardless of whether or not a patient is going to begin therapy immediately they need to enter into care. For patients who
have HIV RNA levels of 500–1,000 copies/mL, resistance testing also may be considered, even though
amplification may not always be successful (BII). If therapy is deferred, repeat testing at the time of
antiretroviral initiation should be considered (CIII).

Patients living with HIV infection must often cope with multiple social, psychiatric, and medical issues that are best
addressed through a multidisciplinary approach to the disease. The evaluation also must include assessment of
substance abuse, economic factors (e.g., unstable housing), social support, mental illness, comorbidities, high-risk behaviors, and other factors that are known to impair the ability to adhere to treatment and to promote education about HIV Once evaluated, these factors should be managed accordingly.
Lastly,  risk behaviors and effective strategies to prevent HIV transmission. to others should be
provided at all a patient’s clinical visits.

Tags: , ,